Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects
Curative surgical treatments, mainly liver resection, are still one of the optimal options for patients with early-, mid-, and even progression-stage hepatocellular carcinoma (HCC). However, the recurrence rate within 5 years after surgery is as high as 70%, especially in patients with high risk fac...
Main Authors: | Bin Guo, Qian Chen, Zhicheng Liu, Xiaoping Chen, Peng Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1098958/full |
Similar Items
-
Network meta-analysis of adjuvant treatments for patients with hepatocellular carcinoma after curative resection
by: Yanyan Ye, et al.
Published: (2023-09-01) -
Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects
by: Xiao-Dong Zhu, et al.
Published: (2020-09-01) -
The Current and Prospective Adjuvant Therapies for Hepatocellular Carcinoma
by: Jeng-Shiun Du, et al.
Published: (2024-04-01) -
Which factors predict tumor recurrence and survival after curative hepatectomy in hepatocellular carcinoma? Results from a European institution
by: Sascha Vaghiri, et al.
Published: (2024-04-01) -
Pre- to postoperative alpha-fetoprotein ratio-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma
by: Chengkai Yang, et al.
Published: (2023-04-01)